Synapsin
Well-known member
- Awards
- 2
Apresflex® - The Next-Gen, Patented, Super-Charged Boswellia Serrata extract
The human body has two major inflammatory pathways, either through 1) the activation of the LOX or 2) the activation of the COX enzyme (some of you may recognize this as COX-1 and COX-2). The major difference between the two is how spread out they are through the human body (COX being far more spread out than LOX). Boswellia serrata is has a unique mechanism of action, specifically inhibiting the LOX inflammation enzyme.
LOX is traditionally in the most injured areas of the body, so because Boswellia serrata targets LOX and not COX, it avoids the unwanted side effects of systemic wide COX inhibition, while still stopping inflammation where it’s really needed, your muscles. Boswellia is the most promising of the natural LOX inhibitors on the market (1).
So you’re sitting there, thinking that’s good and all, but what about actual results? Well…
Apresflex® has studies in humans showing there were significant effects on pain reduction and an increase in physical function in subjects who took 100 mg Apresflex(®) for 90 days in a double blind, randomized controlled trial (2). They noted subjects noticed a reduction of pain in as little as 7 days! Another study found the same effects in humans taking 100 mg of Apresflex(®) during a 30 day double blind randomized controlled trial, this time noting subjects noticed an improvement in as little as 5 days (3).
Another study in humans found that 100 mg of a patented 5-loxin extract reduced pain and improved physical function in humans. They hypothesized that these effects may be due to a reduction in pro-inflammatory modulators, and an improvement in joint health by reducing enzymatic degradation of cartilage in patients with osteoarthritis (4).
While boswellia extracts are all over the industry, you have no idea if the extraction is actually for the effective components unless it is from the patented Apresflex. Apresflex® not only includes 5-loxin, but includes the strongest anti-inflammatory in Boswellia, AKBA (5). When compared to AKBA alone, Apresflex® showed faster absorption and quicker healing effects, making it the most optimal Boswellia extract on the market (6).
Expect Apresflex® to be the leading joint support ingredient of the future.
References
1. Brower, Vicki. "Ancient Herb Suppresses Inflammation." Life Extension 1 Mar. 2007: n. pag.
2. Sengupta, Krishanu. "Comparative Efficacy and Tolerability of 5-Loxin ® and Aflapin ® Against Osteoarthritis of the Knee: A Double Blind, Randomized, Placebo Controlled Clinical Study." International Journal of Medical Sciences Int. J. Med. Sci. (2010): 366.
3. Vishal, Amar A. "A Double Blind, Randomized, Placebo Controlled Clinical Study Evaluates the Early Efficacy of Aflapin ® in Subjects with Osteoarthritis of Knee." International Journal of Medical Sciences Int. J. Med. Sci. (2011): 615.
4. Sengupta, Krishanu, Krishnaraju V. Alluri, Andey Satish, Simanchala Mishra, Trimurtulu Golakoti, Kadainti Vs Sarma, Dipak Dey, and Siba P. Raychaudhuri. "A Double Blind, Randomized, Placebo Controlled Study of the Efficacy and Safety of 5-Loxin® for Treatment of Osteoarthritis of the Knee." Arthritis Res Ther Arthritis Research & Therapy 10.4 (2008): n. pag.
5. Sailer, E.-R., B. Rall, R.f. Hoemlein, H.p.t. Ammon, and H. Safayhi. "Acetyl-11-keto-beta-boswellic Acid: Structure Requirements for Effector-site Binding and 5-lipoxygenase Inhibitory Activity." Pharmacological Research 31 (1995): 318.
6. PLT Health Solutions. Apresflex- SUPPORTS HEALTHY JOINTS AND CONNECTIVE TISSUES. N.p.: PLT Health Solutions, 2015. Web. <http://www.plthealth.com/sites/plthomas.com/files/ckfinder/userfilesfiles/U-415%20APRESFLEX%20Product%20Sheet.pdf>.
The human body has two major inflammatory pathways, either through 1) the activation of the LOX or 2) the activation of the COX enzyme (some of you may recognize this as COX-1 and COX-2). The major difference between the two is how spread out they are through the human body (COX being far more spread out than LOX). Boswellia serrata is has a unique mechanism of action, specifically inhibiting the LOX inflammation enzyme.
LOX is traditionally in the most injured areas of the body, so because Boswellia serrata targets LOX and not COX, it avoids the unwanted side effects of systemic wide COX inhibition, while still stopping inflammation where it’s really needed, your muscles. Boswellia is the most promising of the natural LOX inhibitors on the market (1).
So you’re sitting there, thinking that’s good and all, but what about actual results? Well…
Apresflex® has studies in humans showing there were significant effects on pain reduction and an increase in physical function in subjects who took 100 mg Apresflex(®) for 90 days in a double blind, randomized controlled trial (2). They noted subjects noticed a reduction of pain in as little as 7 days! Another study found the same effects in humans taking 100 mg of Apresflex(®) during a 30 day double blind randomized controlled trial, this time noting subjects noticed an improvement in as little as 5 days (3).
Another study in humans found that 100 mg of a patented 5-loxin extract reduced pain and improved physical function in humans. They hypothesized that these effects may be due to a reduction in pro-inflammatory modulators, and an improvement in joint health by reducing enzymatic degradation of cartilage in patients with osteoarthritis (4).
While boswellia extracts are all over the industry, you have no idea if the extraction is actually for the effective components unless it is from the patented Apresflex. Apresflex® not only includes 5-loxin, but includes the strongest anti-inflammatory in Boswellia, AKBA (5). When compared to AKBA alone, Apresflex® showed faster absorption and quicker healing effects, making it the most optimal Boswellia extract on the market (6).
Expect Apresflex® to be the leading joint support ingredient of the future.
References
1. Brower, Vicki. "Ancient Herb Suppresses Inflammation." Life Extension 1 Mar. 2007: n. pag.
2. Sengupta, Krishanu. "Comparative Efficacy and Tolerability of 5-Loxin ® and Aflapin ® Against Osteoarthritis of the Knee: A Double Blind, Randomized, Placebo Controlled Clinical Study." International Journal of Medical Sciences Int. J. Med. Sci. (2010): 366.
3. Vishal, Amar A. "A Double Blind, Randomized, Placebo Controlled Clinical Study Evaluates the Early Efficacy of Aflapin ® in Subjects with Osteoarthritis of Knee." International Journal of Medical Sciences Int. J. Med. Sci. (2011): 615.
4. Sengupta, Krishanu, Krishnaraju V. Alluri, Andey Satish, Simanchala Mishra, Trimurtulu Golakoti, Kadainti Vs Sarma, Dipak Dey, and Siba P. Raychaudhuri. "A Double Blind, Randomized, Placebo Controlled Study of the Efficacy and Safety of 5-Loxin® for Treatment of Osteoarthritis of the Knee." Arthritis Res Ther Arthritis Research & Therapy 10.4 (2008): n. pag.
5. Sailer, E.-R., B. Rall, R.f. Hoemlein, H.p.t. Ammon, and H. Safayhi. "Acetyl-11-keto-beta-boswellic Acid: Structure Requirements for Effector-site Binding and 5-lipoxygenase Inhibitory Activity." Pharmacological Research 31 (1995): 318.
6. PLT Health Solutions. Apresflex- SUPPORTS HEALTHY JOINTS AND CONNECTIVE TISSUES. N.p.: PLT Health Solutions, 2015. Web. <http://www.plthealth.com/sites/plthomas.com/files/ckfinder/userfilesfiles/U-415%20APRESFLEX%20Product%20Sheet.pdf>.
